SAW US ON THE TRUCK?

Discover companies building the next
generation of medical innovation

Select Client Portfolio

Clinical stage multi-modality

Treg therapies targeting neurodegenerative, autoimmune, and metabolic diseases

Clinical stage platform designed
to deliver lasting cures for the broadest range of genetic and infectious diseases including
HBV and DMD

Advanced skin-friendly
hydrogels powering wound care, beauty, and device brands with 100% + YoY revenue and expanding margins

Treating medical conditions
that arise due to localized accumulations of excess cholesterol

Clinically validated gene therapy platform restoring function without viral vectors,
immunity, or payload limits

Inflammation-focused biotech with active CDMO revenues

Regenerate. Rewire. Recover. Developing minimally invasive therapies for patient
recovery after CNS injuries

Democratizing venture investing;

Shaping the future of healthcare

Clinical stage 4-in-1 multi-target cell and gene therapy platform solution for complex

multi-factorial diseases

Clinical stage, First-in-Class Inhaled, fast-acting antibody treatments for acute
respiratory Infections

Clinical stage, Off-the-shelf immunotherapy solving the core problems of tumor and

patient heterogeneity

Clinical stage scalable solutions
to revolutionize cell therapy manufacturing

Clinical stage neuroprotective therapies with
the potential to revolutionize the treatment of serious eye and brain diseases

Revolutionary therapy for refractory angina in
coronary heart disease

Clinical stage platform developing life changing medicines for PTSD, Social Anxiety Disorder, Opioid Use Disorder, and Radiculopathic Pain

Eliminates slough, disrupts bacterial biofilm reducing bioburden, and promotes wound bed preparation and healing

Phase 2B/3 study in Venous Leg Ulcers is expected to initiate in 2026

Copyrights 2026 | Allele Capital Partners and Allele Communications LLC